Clinical Trial Update: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Relmacabtagene autoleucel as second-line therapy for adults with aggressive B-cell non-Hodgkin lymphomas is listed as active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Grade 3b
• High-grade B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• Relmacabtagene Autoleucel (relmacabtagene autoleucel)

Snippet

Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd. | Conditions: Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B | Phase 2 | Status: ACTIVE_NOT_RECRUITING